Clinical Trial · NCT01689727

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Overview

Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled study.

Sponsor

Endocyte

Phase

Phase 2

Contacts

Nelson Oyesiku, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01689727

Drug / Compound

EC20

Isotope(s):

Target(s):

FR (Folate Receptor)

Ligand Class: Small Molecules

Eligibility

Inclusion

Subject must have a pituitary tumor.
Subject must be 18 years of age or older.
Subjects must meet the following eligibility requirements to be enrolled in the study:
Subject must have good kidney function.3\. Subject must provide written informed consent prior to enrollment.

Exclusion

Subject is unable to tolerate conditions for radionuclide imaging.
Subject is simultaneously participating in another investigational drug study.
Subject has completed the follow-up phase of any previous study loess than 30 days prior to enrollment in this study.
Subjects must be excluded if any of the following conditions are present:
Subject is pregnant or breastfeeding.